{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:16:30Z","timestamp":1791191790244,"version":"4.1.0"},"reference-count":20,"publisher":"American Psychiatric Association Publishing","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2001,8,1]]},"DOI":"10.1176\/appi.ajp.158.8.1200","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T18:21:35Z","timestamp":1034360495000},"page":"1200-1204","source":"Crossref","is-referenced-by-count":33,"title":["Office-Based Treatment for Opioid Dependence: Reaching New Patient Populations"],"prefix":"10.1176","volume":"158","author":[{"given":"David A.","family":"Fiellin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rosenheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1588BABBGDBJ","doi-asserted-by":"crossref","unstructured":"Mark T, Woody GE, Juday T, Kleber HD: The societal costs of heroin addiction. Drug Alcohol Depend 2001; 61:195-206","DOI":"10.1016\/S0376-8716(00)00162-9"},{"key":"R1588BABGFGEG","doi-asserted-by":"crossref","unstructured":"O\u2019Connor PG, Fiellin DA: Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000; 133:40-54","DOI":"10.7326\/0003-4819-133-1-200007040-00008"},{"key":"R1588BABBHHDI","doi-asserted-by":"crossref","unstructured":"Hubbard RL, Craddock SG, Flynn PM, Anderson J, Etheridge RM: Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997; 11:261-278","DOI":"10.1037\/\/0893-164X.11.4.261"},{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Simpson DD, Joe GW, Brown BS: Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997; 11:294-307","DOI":"10.1037\/\/0893-164X.11.4.294"},{"key":"R1588BABBHDHH","doi-asserted-by":"crossref","unstructured":"Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, Banys P, Hall M: Methadone maintenance vs 180-day psychosocially enriched detoxification for opioid dependence: a randomized controlled trial. JAMA 1999; 283:1303-1310","DOI":"10.1001\/jama.283.10.1303"},{"key":"R1588BABEECBI","doi-asserted-by":"crossref","unstructured":"O\u2019Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ: Three methods of opioid detoxification in a primary care setting. a randomized trial. Ann Intern Med 1997; 127:526-530","DOI":"10.7326\/0003-4819-127-7-199710010-00004"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"O\u2019Connor PG, Kosten TR: Rapid and ultrarapid opioid detoxification techniques. JAMA 1998; 279:229-234","DOI":"10.1001\/jama.279.3.229"},{"key":"R1588BABFBFBD","doi-asserted-by":"crossref","unstructured":"Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE: A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43:72-78","DOI":"10.1038\/clpt.1988.13"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"Jasinski DR, Pevnick JS, Griffith JD: Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35:501-516","DOI":"10.1001\/archpsyc.1978.01770280111012"},{"key":"R1588BABCDEEI","doi-asserted-by":"crossref","unstructured":"Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE: Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569-580","DOI":"10.1038\/clpt.1994.71"},{"key":"R1588BABFFHEI","doi-asserted-by":"crossref","unstructured":"Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D: Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93:475-486","DOI":"10.1046\/j.1360-0443.1998.9344753.x"},{"key":"R1588BABFIAII","doi-asserted-by":"crossref","unstructured":"Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE: A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40:17-25","DOI":"10.1016\/0376-8716(95)01186-2"},{"key":"R1588BABFAFEC","unstructured":"Mello NK, Mendelson JH, Kuehnle JC: Buprenorphine effects on human heroin self-administration: an operant analysis. J Pharmacol Exp Ther 1981; 223:30-39"},{"key":"R1588BABJGHEH","doi-asserted-by":"crossref","unstructured":"Johnson RE, Jaffe JH, Fudala PJ: A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267:2750-2755","DOI":"10.1001\/jama.267.20.2750"},{"key":"R1588BABGAIEA","doi-asserted-by":"crossref","unstructured":"Ling W, Wesson DR, Charuvastra C, Klett CJ: A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53:401-407","DOI":"10.1001\/archpsyc.1996.01830050035005"},{"key":"R1588BABGDFIG","doi-asserted-by":"crossref","unstructured":"Strain EC, Stitzer ML, Liebson IA, Bigelow GE: Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) 1994; 116:401-406","DOI":"10.1007\/BF02247469"},{"key":"R1588BABHIGFE","doi-asserted-by":"crossref","unstructured":"Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J: Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181:358-364","DOI":"10.1097\/00005053-199306000-00004"},{"key":"R1588BABFCAEB","doi-asserted-by":"crossref","unstructured":"Barnett PG, Rodgers JH, Bloch DA: A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001; 96:683-690","DOI":"10.1046\/j.1360-0443.2001.9656834.x"},{"key":"R1588BABHEAJH","doi-asserted-by":"crossref","unstructured":"Reynaud M, Petit G, Potard D, Courty P: Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998; 93:1385-1392","DOI":"10.1046\/j.1360-0443.1998.93913859.x"},{"key":"R1588BABEEAJG","doi-asserted-by":"crossref","unstructured":"Carrieri MP, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, Obadia Y (Manif-2000 Study Group): Use of buprenorphine in HIV-infected injection drug users: negligible impact on virological response to HAART. Drug Alcohol Depend 2000; 60:51-54","DOI":"10.1016\/S0376-8716(00)80007-1"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.158.8.1200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T18:50:30Z","timestamp":1721847030000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.158.8.1200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8,1]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,8,1]]}},"alternative-id":["10.1176\/appi.ajp.158.8.1200"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.158.8.1200","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8,1]]}}}